Coca-Cola Europacific shares lose fizz after interim results

Impact · against what's priced in

CCEP is seeing a mild negative reaction as revenue growth decelerates in Q2, despite meeting overall first-half profit targets. GENF gains support from accelerated US patent examinations, strengthening the protection of its therapeutic pipeline.

GENF+0.30

No priced-in read yet

In context

The acceleration of US patent examination for its SIRT6 gene variant provides material strength to the company's entire therapeutic pipeline protection.

Read from the article alone

• earnings▲<1%
• geopolitics
• guidance
• CCEP
• GENF
• beverages
• food and drink
• middle east
• profit taking